Methotrexate – a disease-modifying antirheumatic drug – is considered a first-line
treatment for psoriatic arthritis, or PsA, but a British study raises questions about whether it actually does anything to slow down the disease.
The study, published in 2012 in the journal Rheumatology, is the first large, double-blind, placebo-controlled study of methotrexate for psoriatic arthritis.